Dr Reddy's Laboratories has received approval to manufacture and market generic semaglutide, a weight loss drug, once Novo Nordisk's patent expires in 2026.
The company is banking on key new launches, including weight loss drug Semaglutide and biosimilar Abatacept to drive growth ...
Against the backdrop of global trade policy uncertainties, even the threat of high tariffs may not be able to stop the upward momentum of certain high-quality stocks. Taking pharmaceutical giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback